FDA Announces Results of Infant Formula Contaminant Testing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy ABT?
The U.S. Food and Drug Administration announced results from the "largest and most rigorous examination ever conducted focused on chemical contaminants in infant formula available on the U.S. market. While breast milk is widely considered the gold standard and optimal source of nutrition for infants whenever possible, millions of parents depend on formula." "We tested more infant formula than ever before, and the results are clear: most products meet a high safety standard-but even small exposures matter for newborns," said Health and Human Services Secretary Robert F. Kennedy, Jr. "We will hold manufacturers accountable, and give parents honest, transparent data they can trust. Protecting our children's health is nonnegotiable." Across the products tested, an overwhelming majority of samples had undetectable or very low levels of contaminants, affirming that the U.S. infant formula supply is safe. The FDA tested more than 300 infant formula samples representative of products sold at retail across the U.S.-generating more than 120,000 data points-for lead, mercury, cadmium, arsenic, pesticides, per- and polyfluoroalkyl substances, and phthalates. The samples, which included powders, ready-to-feed liquids, and concentrated liquids, were rigorously tested and analyzed in FDA laboratories. The FDA will continue to test infant formula as part of Operation Stork Speed and ongoing surveillance of foods, including testing infant formula products that have entered the U.S. market since this initial survey began and conducting additional compliance sampling. Publicly traded companies that make infant formula include Nestle (NSRGY), Danone (DANOY), and Abbott (ABT).
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABT
Wall Street analysts forecast ABT stock price to rise
19 Analyst Rating
17 Buy
2 Hold
0 Sell
Strong Buy
Current: 87.540
Low
136.00
Averages
148.11
High
169.00
Current: 87.540
Low
136.00
Averages
148.11
High
169.00
About ABT
Abbott Laboratories is a global healthcare company. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. It serves people in more than 160 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Abbott Laboratories Attracts Income Investors with 3% Yield
- Dividend Appeal: Abbott Laboratories offers an attractive yield nearing 3%, appealing to income-focused investors while navigating rising cost pressures amidst ongoing business growth.
- Dividend King Status: With over 50 consecutive years of dividend increases, Abbott's record as a Dividend King enhances investor confidence in its long-term value proposition within the healthcare sector.
- Market Performance Analysis: While Abbott's stock isn't considered a bargain, its performance remains noteworthy, particularly when compared to other high-return stocks, indicating robust investment potential.
- Investment Recommendations: Although Abbott was not included in The Motley Fool Stock Advisor's top stock picks, its established position in the healthcare industry and history of dividend growth still make it a noteworthy investment consideration.
See More
Abbott Laboratories Attracts Income Investors
- Yield Approaching 3%: Abbott Laboratories is currently offering a yield nearing 3%, attracting income-focused investors, and despite rising costs, its ongoing business growth remains noteworthy.
- Dividend King Status: As a Dividend King, Abbott has increased its dividends for over 50 consecutive years, a record that not only boosts investor confidence but also indicates the company's strong cash flow and profitability capabilities.
- Market Price Analysis: Market prices as of April 27, 2026, indicate that while the stock isn't a screaming bargain, its stable dividends and growth potential still render it a valuable investment in the healthcare sector.
- Long-Term Growth Potential: Despite current cost pressures, Abbott's business growth and dividend policy suggest strong long-term growth potential, making it a suitable focus for long-term investors.
See More
Executive Stock Transactions Overview
- Executive Stock Purchase: Daniel J. Starks, a director at Abbott Laboratories, acquired 10,000 shares for $926,537 on April 27, 2026, increasing his total holdings to 6.75 million shares, indicating confidence in the company despite a 29% stock price decline this year.
- CFO Transactions: EVP and CFO Philip P. Boudreau disclosed an open-market purchase of 2,200 shares at $91.50 each on April 23, 2026, holding 71,172 shares directly after the transaction, reflecting executive recognition of the company's value.
- Investment Amid Market Decline: S&P Global CEO Martina Cheung purchased 2,322 shares at an average price of $429.93 on April 29, 2026, totaling nearly $1 million, increasing her holdings to 27,518 shares, showcasing a strategy of buying during market lows.
- Multiple Executive Transactions: Executives from International Paper and Charter also made significant stock purchases, acquiring 10,000 shares and 6,936 shares respectively, indicating optimism about their companies' prospects in the current market environment.
See More
Abbott Laboratories: Attractive Dividend Investment Opportunity
- Price Dip Opportunity: Abbott Laboratories' stock has fallen 30% over the past year, currently priced at $89.46, presenting an opportunity for investors to buy on the dip and potentially achieve long-term returns.
- Acquisition-Driven Growth: The company completed a $21 billion acquisition of Exact Sciences in Q1, which is expected to enhance revenue through new products like Cologuard, particularly in the colorectal cancer screening market, thereby expanding its market share.
- Innovative Product Line: Abbott's FreeStyle Libre continuous glucose monitoring devices have been a major growth driver, and the launch of new products like Lingo and Libre Rio will help the company penetrate underdeveloped markets, catering to more diabetes patients.
- Stable Dividend Returns: As a Dividend King, Abbott Laboratories has increased its dividend for 50 consecutive years, with a current yield of 2.8%, significantly above the S&P 500's 1.1%, providing investors with a reliable cash flow.
See More
Abbott Laboratories Stock Down 30%: A Long-Term Buy Opportunity
- Stock Price Decline: Abbott Laboratories' stock has fallen 30% over the past year, primarily due to slow growth in its nutrition and diagnostics segments, with only 3.7% comparable sales growth in Q1, which has impacted investor confidence.
- Acquisition-Driven Growth: The company completed a $21 billion acquisition of Exact Sciences in Q1, introducing new products like Cologuard for colorectal cancer testing, which is expected to leverage Abbott's strong healthcare presence to drive growth and expand market share.
- Innovative Product Line: Abbott's FreeStyle Libre continuous glucose monitoring devices have been a major growth driver in recent years, and with the CGM market still underpenetrated, the launch of new over-the-counter CGM products like Lingo and Libre Rio will further target populations and enhance sales potential.
- Dividend Attractiveness: As a
See More
Multiple Companies Hit 52-Week Lows Amid Sector Concerns
- Abbott Stock Decline: Abbott Laboratories (ABT) shares fell to a 52-week low of $90.29 during intraday trading, primarily due to declining demand for Covid-19 testing and market share losses in pediatric nutrition, resulting in a more than 26% drop in stock price this year.
- Figma Stock Fluctuation: Figma Inc. (FIG) hit a 52-week low of $16.60 on Thursday but rebounded to $17.70 at close, as retail investors largely dismissed concerns over its AI design tool, indicating a potential upside of about 127% based on a 12-month average price target of $40.25 from analysts.
- International Paper's Poor Performance: International Paper Co. (IP) shares fell to a fresh 52-week low of $29.45 after posting Q1 EBITDA of $677 million, which was 3% below consensus and significantly below its own guidance, contributing to a more than 24% decline in stock price this year.
- Market Sentiment Analysis: Despite the ongoing declines in Abbott and International Paper's stock prices, retail sentiment on Stocktwits remains bearish for Abbott, particularly with high message volumes indicating market concerns about its future performance.
See More
Abbott Laboratories Attracts Income Investors with 3% Yield
- Dividend Appeal: Abbott Laboratories offers an attractive yield nearing 3%, appealing to income-focused investors while navigating rising cost pressures amidst ongoing business growth.
- Dividend King Status: With over 50 consecutive years of dividend increases, Abbott's record as a Dividend King enhances investor confidence in its long-term value proposition within the healthcare sector.
- Market Performance Analysis: While Abbott's stock isn't considered a bargain, its performance remains noteworthy, particularly when compared to other high-return stocks, indicating robust investment potential.
- Investment Recommendations: Although Abbott was not included in The Motley Fool Stock Advisor's top stock picks, its established position in the healthcare industry and history of dividend growth still make it a noteworthy investment consideration.
See More
Abbott Laboratories Attracts Income Investors
- Yield Approaching 3%: Abbott Laboratories is currently offering a yield nearing 3%, attracting income-focused investors, and despite rising costs, its ongoing business growth remains noteworthy.
- Dividend King Status: As a Dividend King, Abbott has increased its dividends for over 50 consecutive years, a record that not only boosts investor confidence but also indicates the company's strong cash flow and profitability capabilities.
- Market Price Analysis: Market prices as of April 27, 2026, indicate that while the stock isn't a screaming bargain, its stable dividends and growth potential still render it a valuable investment in the healthcare sector.
- Long-Term Growth Potential: Despite current cost pressures, Abbott's business growth and dividend policy suggest strong long-term growth potential, making it a suitable focus for long-term investors.
See More
Executive Stock Transactions Overview
- Executive Stock Purchase: Daniel J. Starks, a director at Abbott Laboratories, acquired 10,000 shares for $926,537 on April 27, 2026, increasing his total holdings to 6.75 million shares, indicating confidence in the company despite a 29% stock price decline this year.
- CFO Transactions: EVP and CFO Philip P. Boudreau disclosed an open-market purchase of 2,200 shares at $91.50 each on April 23, 2026, holding 71,172 shares directly after the transaction, reflecting executive recognition of the company's value.
- Investment Amid Market Decline: S&P Global CEO Martina Cheung purchased 2,322 shares at an average price of $429.93 on April 29, 2026, totaling nearly $1 million, increasing her holdings to 27,518 shares, showcasing a strategy of buying during market lows.
- Multiple Executive Transactions: Executives from International Paper and Charter also made significant stock purchases, acquiring 10,000 shares and 6,936 shares respectively, indicating optimism about their companies' prospects in the current market environment.
See More
Abbott Laboratories: Attractive Dividend Investment Opportunity
- Price Dip Opportunity: Abbott Laboratories' stock has fallen 30% over the past year, currently priced at $89.46, presenting an opportunity for investors to buy on the dip and potentially achieve long-term returns.
- Acquisition-Driven Growth: The company completed a $21 billion acquisition of Exact Sciences in Q1, which is expected to enhance revenue through new products like Cologuard, particularly in the colorectal cancer screening market, thereby expanding its market share.
- Innovative Product Line: Abbott's FreeStyle Libre continuous glucose monitoring devices have been a major growth driver, and the launch of new products like Lingo and Libre Rio will help the company penetrate underdeveloped markets, catering to more diabetes patients.
- Stable Dividend Returns: As a Dividend King, Abbott Laboratories has increased its dividend for 50 consecutive years, with a current yield of 2.8%, significantly above the S&P 500's 1.1%, providing investors with a reliable cash flow.
See More
Abbott Laboratories Stock Down 30%: A Long-Term Buy Opportunity
- Stock Price Decline: Abbott Laboratories' stock has fallen 30% over the past year, primarily due to slow growth in its nutrition and diagnostics segments, with only 3.7% comparable sales growth in Q1, which has impacted investor confidence.
- Acquisition-Driven Growth: The company completed a $21 billion acquisition of Exact Sciences in Q1, introducing new products like Cologuard for colorectal cancer testing, which is expected to leverage Abbott's strong healthcare presence to drive growth and expand market share.
- Innovative Product Line: Abbott's FreeStyle Libre continuous glucose monitoring devices have been a major growth driver in recent years, and with the CGM market still underpenetrated, the launch of new over-the-counter CGM products like Lingo and Libre Rio will further target populations and enhance sales potential.
- Dividend Attractiveness: As a
See More
Multiple Companies Hit 52-Week Lows Amid Sector Concerns
- Abbott Stock Decline: Abbott Laboratories (ABT) shares fell to a 52-week low of $90.29 during intraday trading, primarily due to declining demand for Covid-19 testing and market share losses in pediatric nutrition, resulting in a more than 26% drop in stock price this year.
- Figma Stock Fluctuation: Figma Inc. (FIG) hit a 52-week low of $16.60 on Thursday but rebounded to $17.70 at close, as retail investors largely dismissed concerns over its AI design tool, indicating a potential upside of about 127% based on a 12-month average price target of $40.25 from analysts.
- International Paper's Poor Performance: International Paper Co. (IP) shares fell to a fresh 52-week low of $29.45 after posting Q1 EBITDA of $677 million, which was 3% below consensus and significantly below its own guidance, contributing to a more than 24% decline in stock price this year.
- Market Sentiment Analysis: Despite the ongoing declines in Abbott and International Paper's stock prices, retail sentiment on Stocktwits remains bearish for Abbott, particularly with high message volumes indicating market concerns about its future performance.
See More
